In Vivo Directed Evolution of Adeno-Associated Virus Vectors for Glioblastoma Multiforme Tumor-Initiating Cells
多形性胶质母细胞瘤肿瘤起始细胞腺相关病毒载体的体内定向进化
基本信息
- 批准号:9353802
- 负责人:
- 金额:$ 22.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-16 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAnatomyAnimal ModelAnimalsApoptosisAstrocytomaBiodistributionBiologicalBlood - brain barrier anatomyBrain NeoplasmsCancer ModelCapsid ProteinsCellsClinicClinicalClinical TrialsDependovirusDevelopmentDiagnosisDiffuseDirected Molecular EvolutionDiseaseDistalEngineeringEssential GenesEvolutionExcisionFamilial Lipoprotein Lipase DeficiencyFutureGene DeliveryGene LibraryGenerationsGeneticGenetic EnhancementGlioblastomaGliomaGrowthHemophilia AHerpesviridaeHumanImmunocompromised HostIn VitroIndividualInjectableInjection of therapeutic agentInterventionLeber&aposs amaurosisLibrariesMalignant NeoplasmsMediatingMedicalMendelian disorderModelingMolecularMolecular VirologyMusNeoplasm MetastasisNeuraxisOncolyticOperative Surgical ProceduresPatientsPre-Clinical ModelPrimary Brain NeoplasmsPropertyProtein EngineeringRadiationRecoverySafetySeriesSuicideSystemTherapeuticTimeTissuesTreatment EfficacyTropismTumor InitiatorsVacciniaVariantViralViral GenomeViral VectorVirusWorkXenograft ModelXenograft procedureadeno-associated viral vectorantiangiogenesis therapybasebrain parenchymacancer immunotherapycancer therapychemotherapyclinical translationconventional therapyexperienceextracellulargene therapyimmune checkpoint blockadeimprovedin vivoin vivo Modelmouse modelneoplastic cellnext generationnovelnovel strategiesoutcome forecastparticleresponsesuccesstargeted deliverytargeted treatmenttherapeutic genetherapeutic targettherapy resistanttraffickingtransgene expressiontumortumor growthtumor progressionvectorvirtual
项目摘要
Summary
Glioma, the most common brain tumor in adults, develops as a result of aberrant growth and invasion of
astrocytic tumor cells. Even with aggressive treatment, survival is very poor and is attributed to the presence
of therapy-resistant tumor-initiating cells (TICs), which are highly migratory and invasive and thus render
complete surgical tumor removal impossible. Engineering therapies that target glioma tumor cells and TICs
may enable enhanced efficacy and as a result longer clinical survival times in patients afflicted with this
disease. Accordingly, this proposal is focused on the development of gene therapy strategies for glioblastoma
multiforme (GBM), an aggressive form of glioma, based on the targeting of GBM tumor cells and TICs.
Adeno-associated virus (AAV) has emerged as a safe and promising vector for gene delivery
applications. However, viral vectors in general, and AAV in particular, do not display strong intrinsic cell tropism
for glioma cells in the central nervous system (CNS), and in addition they experience a number of delivery and
transport barriers for systemic delivery to clinical GBM, including biodistribution to the CNS, the blood brain
barrier, and intraparenchymal and intratumoral transport to the primary and diffuse secondary tumors. Thus, it
is highly desirable to develop vectors that can be systemically delivered and that are capable of overcoming
these delivery barriers.
We propose to engineer the coat proteins of AAV to target delivery to glioma tumor cells and TICs to
greatly enhance delivery efficiency and reduce any biological off-target effects. We hypothesize that AAV
directed evolution, a strategy we originally developed and have successfully employed to enhance viral vector
properties, can be implemented to engineer AAV vectors in vivo for enhanced and potentially selective tropism
for GBM tumor cells and TICs. Specifically, we propose to harness (1) a mouse model based on the
xenografting of primary cultured, patient-derived GBM TICs that accurately represents the hallmarks of GBM,
(2) highly diverse AAV vector libraries, and (3) a sophisticated directed evolution strategy that includes a
stringent in vivo selection selective for viral particles that can localize to the CNS and transduce GBM tumor
cells and TICs. We have successfully recovered viral genomes from the first round of evolution, highlighting the
potential of this strategy. We also propose to characterize the resulting engineered AAV vectors by studying
their tropism and biodistribution, essential gene delivery properties for clinical implementation.
Furthermore, we propose to evaluate the therapeutic potential of engineered AAVs by delivering two
promising therapeutic genes that can hamper tumor progression and extend the survival of our animal models,
or that offer promise in future exploration of cancer immunotherapies. This blend of molecular virology, protein
engineering, and a translationally accurate animal model will therefore enable the engineering of enhanced
genetic delivery systems for the treatment of glioblastoma multiforme and in the future potentially other
cancers.
总结
神经胶质瘤是成人最常见的脑肿瘤,由于神经胶质细胞的异常生长和侵袭而发生。
星形胶质细胞肿瘤细胞即使采用积极的治疗,生存率也很低,这是由于
治疗抗性肿瘤起始细胞(TIC),具有高度迁移性和侵袭性,因此使
手术切除肿瘤是不可能的靶向胶质瘤肿瘤细胞和TIC的工程疗法
可以提高疗效,并因此延长患有这种疾病的患者的临床存活时间。
疾病因此,本建议集中于胶质母细胞瘤基因治疗策略的发展
多形性胶质瘤(GBM)是一种侵袭性形式的胶质瘤,其基于靶向GBM肿瘤细胞和TIC。
腺相关病毒(Adeno-associated virus,AAV)是一种安全、有前途的基因载体
应用.然而,一般的病毒载体,特别是AAV,不显示强的内在细胞向性
对于中枢神经系统(CNS)中的神经胶质瘤细胞,此外,它们经历了许多递送,
全身递送至临床GBM的转运屏障,包括生物分布至CNS、血脑
屏障、实质内和肿瘤内转运至原发性和弥漫性继发性肿瘤。因此
非常需要开发能够全身递送并且能够克服
这些交付障碍。
我们提出改造AAV的外壳蛋白以靶向递送至神经胶质瘤肿瘤细胞和TIC,
大大提高了递送效率并减少了任何生物脱靶效应。我们假设AAV
定向进化,我们最初开发并成功用于增强病毒载体的策略,
特性,可以实施以在体内工程化AAV载体,用于增强的和潜在的选择性向性
GBM肿瘤细胞和TIC。具体来说,我们建议利用(1)基于
异种移植原代培养的患者来源的GBM TIC,其准确地代表GBM的标志,
(2)高度多样性的AAV载体文库,和(3)复杂的定向进化策略,其包括
对可定位于CNS和GBM肿瘤的病毒颗粒具有严格的体内选择性
细胞和TIC。我们已经成功地从第一轮进化中恢复了病毒基因组,
这一战略的潜力。我们还建议通过研究来表征所得到的工程化AAV载体。
它们的向性和生物分布、临床实施的基本基因递送性质。
此外,我们建议通过递送两种重组腺相关病毒来评估工程化腺相关病毒的治疗潜力。
有希望的治疗基因,可以阻止肿瘤的进展,延长我们的动物模型的生存期,
或者为未来癌症免疫疗法的探索提供希望。这种分子病毒学蛋白质
因此,精确的动物模型将使工程化的增强
用于治疗多形性胶质母细胞瘤的遗传传递系统,以及将来可能用于治疗其他胶质母细胞瘤的遗传传递系统。
癌的
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Genome-wide activation screens to increase adeno-associated virus production.
全基因组激活筛选以增加与腺相关的病毒产生。
- DOI:10.1016/j.omtn.2021.06.026
- 发表时间:2021-12-03
- 期刊:
- 影响因子:0
- 作者:Barnes CR;Lee H;Ojala DS;Lewis KK;Limsirichai P;Schaffer DV
- 通讯作者:Schaffer DV
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID V SCHAFFER其他文献
DAVID V SCHAFFER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID V SCHAFFER', 18)}}的其他基金
Biology and Biotechnology of Cell and Gene Therapy
细胞和基因治疗生物学和生物技术
- 批准号:
10090424 - 财政年份:2021
- 资助金额:
$ 22.46万 - 项目类别:
Engineering AAV Vectors to Evade Antibody Neutralization
设计 AAV 载体以逃避抗体中和
- 批准号:
7849654 - 财政年份:2007
- 资助金额:
$ 22.46万 - 项目类别:
Engineering AAV Vectors to Evade Antibody Neutralization
设计 AAV 载体以逃避抗体中和
- 批准号:
7442123 - 财政年份:2007
- 资助金额:
$ 22.46万 - 项目类别:
Engineering AAV Vectors to Evade Antibody Neutralization
设计 AAV 载体以逃避抗体中和
- 批准号:
7208807 - 财政年份:2007
- 资助金额:
$ 22.46万 - 项目类别:
Engineering AAV Vectors to Evade Antibody Neutralization
设计 AAV 载体以逃避抗体中和
- 批准号:
7626787 - 财政年份:2007
- 资助金额:
$ 22.46万 - 项目类别:
Engineering AAV Vectors to Evade Antibody Neutralization
设计 AAV 载体以逃避抗体中和
- 批准号:
7851669 - 财政年份:2007
- 资助金额:
$ 22.46万 - 项目类别:
Engineering Novel AAV Vectors for Retinal Gene Therapy
用于视网膜基因治疗的新型 AAV 载体工程
- 批准号:
7268010 - 财政年份:2006
- 资助金额:
$ 22.46万 - 项目类别:
Engineering Novel AAV Vectors for Retinal Gene Therapy
用于视网膜基因治疗的新型 AAV 载体工程
- 批准号:
7149417 - 财政年份:2006
- 资助金额:
$ 22.46万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 22.46万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 22.46万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 22.46万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 22.46万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 22.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 22.46万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 22.46万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 22.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 22.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 22.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




